Oh Young Bang/LinkedIn
Oct 6, 2025, 03:41
Oh Young Bang: We Are Carefully Preparing to Begin the First Cinical Trial of Exosome Therapy for Stroke in Korea
Oh Young Bang, Professor of Neurology at Samsung Medical Center, CEO at S and E bio, shared on LinkedIn:
”We are carefully preparing to begin the first clinical trial of exosome therapy for stroke in Korea, prioritizing safety over speed.”
Read more on the announcement here.
S and E Bio, a biotechnology company focused on exosomal microRNA-based therapies, has obtained approval from Korea’s Ministry of Food and Drug Safety (MFDS) to begin a Phase 1b clinical trial of its investigational stroke treatment, SNE-101.
This marks the first exosome-based therapy in Korea to advance to clinical trials, representing a significant milestone in the nation’s biopharmaceutical industry.
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 14:58When Early Diagnosis Is the First Step in Hemophilia A Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper
-
Apr 16, 2026, 13:14Veronica Sanchez: Blood Pressure Categories for Individuals Who Are Pregnant
-
Apr 16, 2026, 13:07Abdul Mannan: Acute Anaphylactic Reaction During Blood Transfusion
-
Apr 16, 2026, 09:41Wolfgang Miesbach: Adeno-Associated Virus Neutralizing Antibodies and Their Clinical Impact on Gene Therapy
-
Apr 16, 2026, 09:33Jeyaraj Pandian: Low-Cost Stroke Rehabilitation Technologies at MENA-VINM 2026